SPOTLIGHT: FDA deems Medtronic warning a 'recall'

Oh, by the way, that was a recall. The FDA tells Medtronic that its January warning to doctors--of the increased inflammation risk when its drug infusion systems SynchroMed and IsoMed were used with certain meds--would be classified as a Class I recall. The categorization doesn't change the warning or its recommendations. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.